Get started
Author

Margaret Elena Gatti-Mays

Observed names: Gatti-Mays, Margaret, M E Gatti-Mays, M. E. Gatti-Mays, M. Gatti-Mays, M.E. Gatti-Mays, Margaret E Gatti-Mays, Margaret E. Gatti-Mayes, Margaret E. Gatti-Mays, Margaret E. Gatti‐Mays, Margaret Gatti-Mays, Margaret Gatti‐Mays, Margaret Gatty-Mays
Observed institutions: National Institutes of Health, Georgetown University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Georgetown University Medical Center, MedStar Georgetown University Hospital, The Ohio State University Wexner Medical Center, Moffitt Cancer Center, Cancer Consortium, National Cancer Institute, National Cancer Institute, Center for Cancer Research, Pelotonia, The Ohio State University
ORCID: 0000-0001-8914-2897
Observed ORCID: 0000-0001-8914-2897
OpenAlex ID: A5022515427
Current Landscape of Immunotherapy in Breast Cancer
2019 · Sylvia Adams, Margaret E. Gatti-Mays, et al. · JAMA Oncology · 382
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
2019 · Marijo Bilusic, Christopher R. Heery, et al. · Journal for ImmunoTherapy of Cancer · 274
PDF
If we build it they will come: targeting the immune response to breast cancer
2019 · Margaret E. Gatti-Mays, Justin M. Balko, et al. · npj Breast Cancer · 207
PDF
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
2021 · Michael A. Thompson, Jeffrey P. Henderson, et al. · JAMA Oncology · 191
PDF
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
2020 · Julius Strauss, Margaret E Gatti-Mays, et al. · Journal for ImmunoTherapy of Cancer · 153
PDF
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
2022 · Yi Wang, Kai Conrad Cecil Johnson, et al. · Journal of Hematology & Oncology · 134
PDF
Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
2017 · Margaret E. Gatti-Mays, Jason M. Redman, et al. · Human Vaccines & Immunotherapeutics · 116
PDF
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
2019 · Alexandra S. Zimmer, Erin Nichols, et al. · Journal for ImmunoTherapy of Cancer · 113
PDF
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
2019 · David B. Page, Harry Bear, et al. · npj Breast Cancer · 84
PDF
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
2021 · Leisha A Emens, Sylvia Adams, et al. · Journal for ImmunoTherapy of Cancer · 82
PDF
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer
2022 · Julie Fu, Sonya A. Reid, et al. · JAMA Network Open · 66
PDF
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
2019 · Margaret E. Gatti-Mays, Jason M. Redman, et al. · The Oncologist · 63
PDF
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules
2019 · Margaret E. Gatti-Mays, Julius Strauss, et al. · Clinical Cancer Research · 61
A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer
2020 · Margaret E. Gatti-Mays, Fatima H. Karzai, et al. · The Oncologist · 57
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19
2022 · Ziad Bakouny, Chris Labaki, et al. · JAMA Oncology · 54
PDF
A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer
2022 · Jason M Redman, Yo-Ting Tsai, et al. · The Oncologist · 44
Chemotherapy-induced gut microbiome disruption, inflammation, and cognitive decline in female patients with breast cancer
2024 · L.D. Otto-Dobos, C.V. Grant, et al. · Brain Behavior and Immunity · 40
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19
2021 · Andrew L. Schmidt, Matthew D. Tucker, et al. · JAMA Network Open · 38
PDF
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
2024 · Filipa Lynce, Candace Mainor, et al. · Nature Communications · 33
PDF
Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8 + T cell antitumor immunity
2022 · Anqi Li, Yuzhou Chang, et al. · Journal for ImmunoTherapy of Cancer · 31
PDF
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance
2020 · Maheen Abidi, David M. Aboulafia, et al. · Cancer Cell · 31
PDF
Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors
2019 · Julie M. Collins, Renee N. Donahue, et al. · The Oncologist · 29
PDF
Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases
2022 · Ilana Schlam, Margaret E Gatti-Mays · The Oncologist · 26
PDF
Analysis of breast cancer in young women in the Department of Defense (DOD) database
2017 · Alexandra S. Zimmer, Kangmin Zhu, et al. · Breast Cancer Research and Treatment · 26
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer
2024 · Lauren D. Otto-Dobos, Lindsay D. Strehle, et al. · npj Breast Cancer · 25
PDF
Works count: 199
Citation count: 2,846
H-index: 25
I10-index: 45
Year
Topic
Type